| Project/Area Number |
24659564
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
SAJI Hideo 京都大学, 薬学研究科(研究院), 教授 (40115853)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
小野 正博 京都大学, 薬学研究科, 准教授 (80336180)
天満 敬 京都大学, 薬学研究科, 助教 (90378787)
木村 寛之 京都大学, 放射性同位元素総合センター, 助教 (50437240)
上田 真史 岡山大学, 医歯薬学総合研究科, 准教授 (40381967)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | タウオパチー / GSK-3β / 認知症 / イメージング / 診断 |
|---|
| Research Abstract |
In this study, to develop nuclear medical imaging probes targeting GSK-3beta, we newly designed and synthesized 125I-labeled compound based on maleimide scaffold ([125I]7). In biodistribution study in normal mice, [125I]7 showed high brain uptake sufficient for in vivo imaging of GSK-3beta. In addition, in in vitro binding assay using GSK-3beta, compound 7 displayed higher binding affinity for GSK-3beta than indirubin-3'-oxime reported previously as a GSK-3beta inhibitor. These results in this study suggest that it will be feasible to develop nuclear medical imaging probes targeting GSK-3beta by further optimizing the chemical structure.
|
